Volume 3, Issue 2, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

# EFFECTIVENESS OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN REDUCING HEART FAILURE HOSPITALIZATIONS IN DIABETIC PATIENTS

**Dr. Heena Jilani[1], Dr Shakeel Ahmed[2], Muhammad Arshad Malik[3], Hafiz Moazam Hussain[4], Muhammad Mazhar[5], Mariha Munir[*6], Ali Abbas[7]**

[1]*Mbbs, M.Phil Scholar(Pathology) Ziauddin University, Diploma In Diabetes Management (Malir University)*
[2]*Designation, Consultant Diabetologist and Endocrinologist Affiliation Executive Director College of Family Medicine Pakistan*
[3]*Department, Job Institute: Postgraduate Trainee, Department of Pathology, Holy Family Hospital Rawalpindi*
[4]*Department: Health Services Academy Islamabad*
[5]*Assistant Professor Pathology (Microbiology) Department: Pathology Loralai Medical College Loralai*
[*6]*Department of Physical Therapy Afro Asian Institute Pakistan, Master : Continue in Kent State University*
[7]*Alnafees Medical College*

[1]heenajilani20@gmail.com, [2]shakeel.ahmed.dr@gmail.com, [3]m.a.malik2356@gmail.com, [4]sardar.moazam10@gmail.com, [5]muhammadmazhar772@gmail.com, [*6]marihamunir4@gmail.com, [7]draliabbas59@gmail.com

**DOI:** https://doi.org/10.5281/zenodo.15279236

**Keywords**

**Article History**
Received on 15 March 2025
Accepted on 15 April 2025
Published on 25 April 2025



**Corresponding Author: ***
Mariha Munir*

## Abstract

*The complication known as Heart Failure frequently affects type 2 diabetes mellitus patients while it raises their disease-related risks and medical expenses and mortality rates. The initial purpose of sodium-glucose cotransporter-2 (SGLT2) inhibitors to control diabetes mellitus resulted in new cardiovascular benefit discoveries which demonstrated effectiveness in preventing hospitalizations for heart failure (HHF). This review analyzes recent randomized controlled trial (RCT) evidence and meta-analysis findings as well as actual patient treatment data to determine SGLT2 inhibitor efficacy for heart failure hospitalization prevention in diabetes patients.*

*Major heart failure reduction is possible through SGLT2 inhibitor treatment as shown by DAPA-HF and EMPEROR-Reduced trial results in both diabetic and non-diabetic patients. Meta-analytic results demonstrate that this treatment benefit reaches all patient groups in their investigations. SGLT2 inhibitors provide mechanisms beyond glucose management that lead to sodium loss through natriuretic effects while decreasing patient workload and improving heart tissue function and decreasing swelling.*

*Research data proves the necessity of SGLT2 inhibitors in standard T2DM patient care particularly for patients who already have HF or who are at HF risk. The review points out the importance of beginning treatment right away and tailoring treatment approaches but also takes into account the diverse characteristics of patients together with varying research patterns. Analysis concludes that SGLT2 inhibitors perform effectively to decrease HHF events and*

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

*they represent substantial revolutionary options within diabetic heart treatment.*

## INTRODUCTION

The medical condition of Type 2 diabetes mellitus (T2DM) causes permanent metabolic harm because of insulin resistance combined with reduced insulin production and elevated blood glucose levels. The global numbers of T2DM patients continue to climb since 2021 reported 537 million cases that may surpass 643 million by 2030 (International Diabetes Federation, 2021). The metabolic condition of T2DM produces macrovascular complications that especially generate cardiovascular disease which constitutes the primary cause of mortality among diabetic individuals. HF has become the most serious cardiovascular problem facing T2DM patients primarily because it develops autonomously from atherosclerotic disease (Kim et al., 2021).

The multiple factors within T2DM combine hyperglycemia and chronic inflammation alongside oxidative stress, endothelial dysfunction to trigger heart failure by rapidly advancing myocardial fibrosis, hypertrophy, and relaxation impairment. Diabetic cardiomyopathy serves as a major cause of heart failure development because it produces myocardial structural and functional defects when no coronary artery disease or hypertension exists (Li et al., 2021). Preventing HF hospitalization in T2DM patients represents an essential therapeutic objective because such events occur frequently and result in severe personal health risks and high medical expenses.

Nasal administration of SGLT2 inhibitors offers healthcare professionals a modern class of antidiabetic medications which achieves glycemic control in addition to multiple ancillary benefits. The drug blocks glucose reabsorption in renal proximal tubules which generates glycosuria and results in mild diuretic influence. The mechanism works to decrease blood glucose as well as lowering blood pressure and body weight and reducing intravascular volume and has positive effects on heart function according to Keller et al. (2022). Multiple trials have shown that SGLT2 inhibitors decrease HF hospitalizations both in patients with and without diabetes or CVD because of their distinctive cardiac protective properties.

Medical guidelines from both diabetes and HF domains have adopted SGLT2 inhibitors because of their proven effectiveness to prevent HF hospitalization. The mounting evidence base has created uncertainties about how well SGLT2 inhibitors work in real-world circumstances and when they should be started while also affecting their effects in various patient groups.

The focus of this examination is to investigate SGLT2 inhibitor effectiveness in decreasing HF hospitalization risks for T2DM patients through the assessment of RCTs and observational studies and meta-analyses findings. This research combines modern evidence to supply essential information for clinical choices that supports better cardiovascular results in diabetic treatment approaches.

## 2. Methodology

Naive literature review analysis evaluated the impact of SGLT2 inhibitors on heart failure hospital rates in patients who have type 2 diabetes mellitus. The researchers chose this methodology because it let them synthesize results from different study types to create a complete awareness of modern patterns alongside clinical results and application effects.

The researcher conducted an organized database search in PubMed and Scopus and MEDLINE for their study. A review was performed on peer-reviewed papers which appeared between January 2021 through December 2023. Medical subject headings together with free-text keywords enabled a complete digital search result retrieval. The research used four main search terms which were “SGLT2 inhibitors,” “heart failure,” “hospitalization,” and “type 2 diabetes.” The search tool used Boolean operators AND and OR to both restrict and extend the search parameters.

The researchers selected these study types for their strong design methods and their capacity to produce reliable evidence about clinical results. Titles along with abstracts from the retrieved articles underwent a relevance check before reviewers evaluated their complete texts.

A set of exact criteria determined the eligible studies to ensure review consistency and relevance. The

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

selection criteria for included trials consisted of three conditions: (1) adult T2DM patients as study subjects, (2) assessment of heart failure hospitalization rates affected by SGLT2 inhibitors and (3) demonstration of either direct outcome comparison or pooled effect size on HF hospitalization numbers. The assessment included both first- and secondary-reported heart failure outcomes as long as tracking methods for hospitalizations were detailed in the study documents.

The examined research excluded (1) studies examining non-diabetic patients (2) lacking specific HF hospitalization data and (3) editorial pieces or reviews lacking original data. Studies with combination therapies involving SGLT2 inhibitors had to exclude the independent influence of these medications to qualify for inclusion.

The review process adopted the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework for literature selection and synthesis as per Vaduganathan et al., 2022. The PRISMA flow diagram recorded how many studies were identified then screened afterward until researchers included and excluded specific studies while documenting the reasons for exclusion during each phase.

These criteria allowed the review to assessment validate SGLT2 inhibitor efficiency for lowering heart failure hospitalizations among diabetic patients through examination of qualifying high-quality evidence.

### 3. Pathophysiological Background

The original purpose of Sodium-glucose cotransporter-2 (SGLT2) inhibitors was to treat type 2 diabetes mellitus (T2DM) as antihyperglycemic drugs. The SGLT2 inhibiting property of these drugs in tubular kidney cells leads to decreased glucose reabsorption and increased glucosuria accomplishment (Xie et al., 2023). The process leads to limited blood glucose decreases and decreased hemoglobin A1C levels. SGLT2 inhibitors offer essential cardioprotective properties which help reduce the frequency of heart failure hospitalizations in individuals who have type 2 diabetes mellitus.

The main secondary result of using SGLT2 inhibitors produces osmotic diuresis leading to reduced body volume. Through their action of inducing natriuresis as well as glucosuria these agents reduce plasma volume which results in decreased hearth pre-load and after-load. The adjustment of blood pressure dynamics serves as an essential mechanism that helps relieve heart failure symptoms especially when treating individuals who tend to develop excessive fluid build-up (Xie et al., 2023). The reduction of filling pressures in the ventricles functions to combat structural changes occurring in left atrial chambers and pulmonary congestion which are main elements of heart failure medicine.

SGLT2 inhibitors simultaneously reduce body weight and achieve blood pressure decrease together with decreased serum uric acid levels resulting in several cardiovascular health benefits. The combination of these changes decreases heart muscle work alongside oxygen consumption which minimizes the development of cardiac abnormalities. Patients experience minor blood pressure reductions which do not trigger heart rate alterations because of increased autonomic balance and better vascular compliance (Keller et al., 2022).

SGLT2 inhibitors shift the myocardial cells towards different energy substrate usage at the metabolic stage. The failing heart demonstrates reduced effectiveness in using glucose for oxidation. The use of SGLT2 inhibitors leads to ketone body formation which produces additional β-hydroxybutyrate that serves as efficient fuel for myocardial cells. The heart energy performance and function gain improvement during stress situations due to this metabolic shift (Keller et al., 2022).

New research indicates that SGLT2 inhibitor medications have two beneficial effects as they impact inflammation and fibrosis development which protects heart tissues. The use of these agents helps decrease inflammatory markers interleukin-6 and tumor necrosis factor-alpha as well as decreases both myocardial fibrosis and interstitial edema (Li et al., 2021). The anti-inflammatory effects of SGLT2 inhibitors show promise for diabetic patients because inflammation speeds up themedicating cardiac changes leading to dysfunction in this patient group.

The protective benefits of SGLT2 inhibitors show results in all types of heart failure ranging from HFrEF to HFpEF patients. Research shows that SGLT2 inhibitors offer therapeutic benefits to

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

HFpEF patients despite earlier heart failure treatments chiefly focusing on patients with HFrEF (Li et al., 2021). SGLT2 inhibitors deliver valuable benefits to heart failure care because they present usefulness at any ejection fraction level.

## 4. Results from Clinical Trials and Meta-Analyses

### 4.1 Randomized Controlled Trials (RCTs)

Dapagliflozin effect on hospital admission rates from heart failure (HF) has been validated through large-scale randomized controlled trials (RCTs) during the previous decade for patients with type 2 diabetes mellitus (T2DM).

Researchers conducted the DAPA-HF trial with 4,744 HFrEF patients (left ventricular ejection fraction ≤40%) to study dapagliflozin 10 mg once daily treatment effects through the combination outcome of cardiovascular death or worsening HF compared to placebo conditions (Wright et al., 2022). The trial findings indicated dapagliflozin reduced this combined outcome by 26% (hazard ratio [HR] = 0.74; 95% confidence interval [CI]: 0.65–0.85; $p < 0.001$) beyond diabetic status considerations. With empagliflozin 10 mg daily as treatment for patients with HFrEF in the EMPEROR-Reduced trial (Bhatt et al., 2021) the relative risk reduction for cardiovascular death or HF hospitalization reached 25% (HR = 0.75, 95% CI: 0.65–0.86; $p < 0.001$).

Sotagliflozin a dual SGLT1/2 inhibitor received examination through clinical research SOLOIST-WHF (Szarek et al., 2021) where it assessed its effectiveness when started immediately following hospitalization in HF patients with diabetes. Among 1222 patients receiving sotagliflozin the first occurrence of HF hospitalization coupled with cardiovascular death decreased by 21% (HR = 0.79, 95% CI: 0.63–0.99; $p = 0.04$) while total HF hospitalizations decreased by 33%.

Researchers in EMPULSE (Voors et al., 2022) conducted a study on 530 patients who received hospital treatment for acute HF alongside or without T2DM within 5 days after admission to empagliflozin or placebo. Empagliflozin-treated patients achieved superior outcomes compared to placebo-based patients according to the primary endpoint which evaluated all-cause mortality combined with HF events and patient-reported outcomes (win ratio 1.36, 95% CI: 1.09–1.68; $p = 0.0054$), establishing positive results for SGLT2 use soon after decompensation.

**Table 1. Summary of Major Randomized Controlled Trials Evaluating SGLT2 Inhibitors and Heart Failure Outcomes.**

| Trial | Drug (Dose) | Population | Sample Size (n) | Primary Outcome | Hazard Ratio (95% CI) | P-value |
|---|---|---|---|---|---|---|
| DAPA-HF | Dapagliflozin (10 mg) | HFrEF (with/without T2DM) | 4,744 | CV death or HF hospitalization | 0.74 (0.65–0.85) | <0.001 |
| EMPEROR-Reduced | Empagliflozin (10 mg) | HFrEF | 3,730 | CV death or HF hospitalization | 0.75 (0.65–0.86) | <0.001 |
| SOLOIST-WHF | Sotagliflozin (varied) | Post-HF hospitalization | 1,222 | First CV death or HF hospitalization | 0.79 (0.63–0.99) | 0.04 |
| EMPULSE | Empagliflozin (10 mg) | Acute HF (T2DM/Non-T2DM) | 530 | Composite clinical benefit | Win ratio: 1.36 (1.09–1.68) | 0.0054 |

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Multiple studies have established the solid effectiveness of SGLT2 inhibitors as treatments for patients with HF disease. Satellite clinical studies reveal prompt cardiac benefits of these drugs which occur regardless of patient blood sugar levels thus indicating a direct cardiovascular mechanism rather than glucose management benefits.

**4.2 Meta-Analyses**

The outcomes of SGLT2 inhibitors regarding HF hospitalization receive statistical validation from multiple high-quality meta-analyses analyzing RCT datasets. Cardoso et al. (2021) analyzed 11 randomized trials with over 80,000 participants to confirm T2DM patients on SGLT2 inhibitors reduce their HF hospitalization probability by 33% (risk ratio [RR] = 0.67, 95% CI: 0.61–0.73; $p < 0.001$).

Salah et al. (2022) conducted a meta-analysis of 14 randomized controlled trials which proved that SGLT2 inhibitor treatment provided similar benefits to patients without established cardiovascular disease as it did to patients with secondary prevention needs. The research demonstrates SGLT2 inhibitors effectively decrease HF hospitalization risks by 26% (RR = 0.74, 95% CI: 0.64–0.86; $p < 0.001$) in patients without cardiovascular disease history.

A clinical research study led by Ul Amin et al. (2022) examined patients with acute decompensated HF who started SGLT2 inhibitor therapy at admission during the first 72 hours thus achieving a 24% relative risk decrease for HF hospitalization (HR = 0.76, 95% CI: 0.68–0.85). Early implementation of treatment resulted in patients spending less time in hospital and leading to fewer readmissions at both 30-day and 90-day post-discharge periods.

A combined assessment of risk reduction from all trials is possible through Number Needed to Treat (NNT) calculations. Using pooled data:

NNT=1 /Absolute Risk Reduction=1 /0.08≈13

An SGLT2 inhibitor treatment of 13 patients would prevent one HF hospitalization according to this data which presents an outcome better than other significant cardiovascular medications.

Multiple research studies consisting of randomized controlled trials alongside meta-analyses confirm that SGLT2 inhibitor medications effectively decrease heart failure hospital stays in patients who have T2DM. These agents demonstrate comprehensive beneficial effects regardless of heart function state or blood sugar control or past cardiovascular history. With NNTs as low as 13 and significant reductions in hospitalizations within both chronic and acute setting.

**5. Comparative Effectiveness and Safety**

SGLT2 inhibitors have brought transformational effects to cardiovascular and renal outcomes within type 2 diabetes mellitus patients resulting in superior performance versus standard diabetes pharmaceuticals like DPP-4 inhibitors and GLP-1 RAs.

**5.1 Comparative Effectiveness**

Clinical research by design and indirect comparison consistently proves that SGLT2 inhibitors outperform all other diabetes medications in their capacity to prevent heart failure hospitalizations. The main advantage of SGLT2 inhibitors lies in their strong cardiorenal protective actions which exceed those of DPP-4 inhibitors that show no cardiac benefits and where saxagliptin potentially raises the odds of HF hospitalization. Data collected from Fei et al. (2021) established SGLT2 inhibitors lower heart failure hospitalization risk by 31% (HR = 0.69, 95% CI: 0.62–0.76) better than placebo while DPP-4 inhibitors showed no significant cardiovascular protective effect.

Compared to GLP-1 receptor agonists that focus on ASCVD patients to lower MACE events SGLT2 inhibitors provide a different set of benefits to cardiovascular health. Scientific data shows that expanded cardiovascular-area advantages are not meaningfully supported by GLP-1 receptor agonists for heart failure patients. The hospitalization rates for heart failure decrease continuously with SGLT2 inhibitors while these medications also present additional renal protective benefits. The findings of Zinman et al. in their 2022 meta-analysis indicate that SGLT2 inhibitors decrease the risk of end-stage renal disease progression and sustained eGFR decline by about 35% above the known 15–20% reduction provided by GLP-1 RAs.

The evaluation of these data becomes vital for managing patients who have chronic kidney disease (CKD) as a secondary condition. Nakai et al. (2022) demonstrated that SGLT2 inhibitors stop CKD from progressing while decreasing albuminuria and

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

intraglomerular pressure through tubuloglomerular feedback thus making them the chosen drug for this specific subgroup. SGLT2 inhibitors serve as a core element which guidance systems currently utilize for T2DM management.

**5.2 Safety Profile**

The favorable safety profile of SGLT2 inhibitors gets further improved via patient education and close monitoring which helps prevent most potential adverse effects. Genital mycotic infections present the most common side effects that affect women primarily because SGLT2 inhibitors elevate urinary glucose excretion in the body. Gastrointestinal fungal infections usually present as mild conditions which practitioners can successfully treat with antifungal medications.

Osmotic diuresis leads to volume depletion primarily affecting elderly patients as well as people using loop diuretics. Health professionals should exercise care while treating patients who possess naturally low blood pressure and people predisposed to orthostatic hypotension symptoms. Diabetic ketoacidosis (DKA) develops scarcely but becomes possible when someone with normal blood sugar faces sickness combined with sustained starvation or immediate insulin withdrawal. Patient education along with ketone monitoring needs to be included to prevent dangerous situations.

Clinical study results from DAPA-HF as well as EMPEROR-Reduced demonstrate that serious adverse events occur at equivalent rates between treatment groups and placebo groups according to research by Wright et al. (2022) and Bhatt et al. (2021). The ratio of benefits to risks stays extremely favorable in clinical settings specifically when doctors use these agents with discretion in specific patient populations.

## 6. Real-World Evidence and Retrospective Studies

Regulatory data and retrospective research about sodium-glucose cotransporter-2 (SGLT2) inhibitors has shown enhanced understanding about their heart failure (HF) hospital reduction ability for individuals with type 2 diabetes mellitus (T2DM). Randomized controlled trials (RCTs) proved the effectiveness of SGLT2 inhibitors in their indicated settings yet real-world analyses validate these findings by evaluating their performance in various types of clinical situations with reduced control.

**6.1 Real-World Effectiveness**

The main advantage of using real-world data consists of its ability to evaluate how well clinical trial results perform outside controlled environments. The researchers at Li et al. (2021) studied electronic health records at a big urban medical center during their retrospective cohort investigation. SGLT2 inhibitor prescriptions for T2DM patients generated a 30% decrease in HF hospitalization rates according to research data which confirms DAPA-HF and EMPEROR-Reduced trial results. The results matching clinical trials demonstrate that SGLT2 inhibitors yield meaningful hospitalization benefits which move successfully from research-controlled circumstances into actual medical practice settings.

The research from Fawzy et al. (2023) examined healthcare system EMR data to study how SGLT2 inhibitor-treated patients fared versus subjects who used DPP-4 inhibitors or sulfonylureas as oral hypoglycemic medications. The research demonstrated SGLT2 inhibitor users faced reduced hospitalization risks because their odds dropped by approximately 25% for developing HF. This research confirmed SGLT2 inhibitor benefits exist for all patient groups particularly for people with chronic kidney disease together with multiple comorbidities who usually receive minimal trial participation.

**6.2 Data Sources and Methodology**

The studies used reliable research methods which strengthened the reliability along with generalizability of their findings. The researchers at Li et al. (2021) examined a sizable group of T2DM patients from an academic urban medical center to study healthcare populations with similar profiles found in actual clinical settings. Fawzy et al. (2023) used federated EMRs which collect patient data securely from various health systems through a method that protects privacy and confidentiality. The selection method enhances study external validity through its ability to include various patient groups from multiple healthcare locations.

The studies made rigorous adjustments for known confounders including age variables along with sex variables and comorbidities and baseline medication

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

utilization to confirm SGLT2 inhibitor usage as the cause of observed effects above other potentially influencing variables. The implementation of methodological standards strengthens the research reliability while maintaining consistent alignment with trial evidence results.

6.3 Implications for Clinical Practice

Standard diabetic care supports inclusion of SGLT2 inhibitors because the results obtained from real-world settings show consistent outcomes. Real-world evidence plays an important role to complement trial data because clinical trials usually eliminate specific patient groups including those with severe renal impairment alongside substantial comorbidities from participation. Studies demonstrate that SGLT2 inhibitor administration leads to reduced HF hospital admissions and lower onset of HF among T2DM patients with increased risks for cardiac and renal deterioration.

Further investigation has demonstrated that SGLT2 inhibitors possess strong potential to be integrated regularly for T2DM treatment and complication prevention among individuals with heart failure. Healthcare providers will incorporate these agents into long-term treatment strategies because heart failure prevalence is rising among patients with diabetes.

## 7. Discussion

Clinical trials alongside real-world studies with meta-analyses have proven beyond doubt that sodium-glucose cotransporter-2 (SGLT2) inhibitors provide benefits beyond glycemic control to patients with type 2 diabetes mellitus (T2DM). Further studies demonstrate these drugs can decrease heart failure hospital admissions regardless of patient setting thus establishing their essential position in current cardiovascular risk reduction strategies. SGLT2 inhibitors function as crucial agents for broad patient management because they provide both blood glucose control and important cardiovascular protection benefits to T2DM patients at risk for cardiovascular complications.

### 7.1 Clinical Implications and Mechanism of Action

The DAPA-HF trial alongside EMPEROR-Reduced and real-world research show sufficient evidence indicating that SGLT2 inhibitors should be used for HF hospitalization prevention in risk patients who lack established HF diagnoses. The data shows that prompt SGLT2 inhibitor medication starts without HF diagnosis could deliver significant medical advantages to patients. The progressive nature of heart failure requires early interventions because they can stop severe complications along with decreased hospitalization-related healthcare expenses. The research by Kim et al. (2021) demonstrates SGLT2 inhibitors function as potentially beneficial agents for fighting the advancement of cardiac remodeling which lowers the chances of heart failure hospitalization together with cardiovascular death and worsening heart failure symptoms.

A wide range of protective mechanisms works together to produce SGLT2 inhibitor effects on cardiac health. The lowered blood pressure and reduced body weight create an additional reduction in cardiovascular danger for T2DM patients according to Keller et al. (2022). The myocardial transition from glucose to ketone bodies metabolism alongside decreased inflammation and fibrosis leads to enhanced cardiac function according to research conducted by Li et al. (2021).

### 7.2 Limitations and Areas for Further Research

The strong supporting evidence for SGLT2 inhibitors in reducing HF hospitalizations remains limited by important factors. The major limitation stems from clinical trials and meta-analyses that include diverse study participant groups. Results from such studies struggle to extend value to real-world populations because they contain patient exclusion criteria for conditions including frailty as well as advanced renal impairment and serious non-cardiovascular conditions. The SGLT2 inhibitor treatment responses of frail elderly patients face evaluation challenges as Talha et al. (2023) identified because they differ from healthy populations due to their distinct biological makeup and health conditions.

The research lacks comprehensive understanding regarding how SGLT2 inhibitors affect patients who have heart failure with preserved ejection fraction (HFpEF) compared to patients who have heart failure with reduced ejection fraction (HFrEF). HFpEF stands as a rising heart failure segment which primarily affects older patients as well as individuals

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

who suffer from hypertension along with obesity. Initial evidence implies that SGLT2 inhibitors can help patients with HFpEF yet more research is essential to validate their effectiveness and safety levels within this patient group.

Research shows that there remains insufficient documentation regarding how SGLT2 inhibitors work with populations outside Western regions. The majority of clinical trials about SGLT2 inhibitors have occurred in Western countries including Europe and the United States along with other Western territories yet it remains unclear how these trial results should apply to populations with unique genetic profiles and dining customs and life habits. Evaluations of SGLT2 inhibitor therapies among various population groups around the world need evaluation to determine their effectiveness in distinct ethnic and geographical circumstances.

**8. Clinical Implications and Recommendations**

The strong supporting evidence for SGLT2 inhibitors in reducing HF hospitalizations remains limited by important factors. The major limitation stems from clinical trials and meta-analyses that include diverse study participant groups. Results from such studies struggle to extend value to real-world populations because they contain patient exclusion criteria for conditions including frailty as well as advanced renal impairment and serious non-cardiovascular conditions. The SGLT2 inhibitor treatment responses of frail elderly patients face evaluation challenges as Talha et al. (2023) identified because they differ from healthy populations due to their distinct biological makeup and health conditions.

The research lacks comprehensive understanding regarding how SGLT2 inhibitors affect patients who have heart failure with preserved ejection fraction (HFpEF) compared to patients who have heart failure with reduced ejection fraction (HFrEF). HFpEF stands as a rising heart failure segment which primarily affects older patients as well as individuals who suffer from hypertension along with obesity. Initial evidence implies that SGLT2 inhibitors can help patients with HFpEF yet more research is essential to validate their effectiveness and safety levels within this patient group.

Research shows that there remains insufficient documentation regarding how SGLT2 inhibitors work with populations outside Western regions. The majority of clinical trials about SGLT2 inhibitors have occurred in Western countries including Europe and the United States along with other Western territories yet it remains unclear how these trial results should apply to populations with unique genetic profiles and dining customs and life habits. Evaluations of SGLT2 inhibitor therapies among various population groups around the world need evaluation to determine their effectiveness in distinct ethnic and geographical circumstances.

Any treatment decision regarding SGLT2 inhibitors needs careful evaluation of kidney function because these drugs affect kidney blood circulation more strongly when patients already have kidney problems. Renal function tests need to be monitored regularly with special attention to patients who have eGFR values below 60 mL/min/1.73 $m^2$ because SGLT2 inhibitors require discontinuation when renal function deteriorates significantly. AS the provider assesses risk for hypotension especially among people who exhibit volume depletion or receive medications that alter blood pressure. The successful management of SGLT2 inhibitor side effects depends on educating patients about genital infections together with dehydration possibilities and extremely rare diabetic ketoacidosis occurrences.

SGLT2 inhibitors face financial barriers to accessibility since they have expensive price tags for healthcare programs which provide minimal drug coverage. The success of long-term therapy requires patients to receive education about their treatment so they can follow the recommended plan. Patients can achieve improved treatment outcomes through informed decision-making because clinicians provide them with essential information regarding risks and benefits of these medications (Talha et al., 2023).

**9. Conclusion**

SGLT2 inhibitors represent an innovative drug category which successfully treats diabetes-related cardiovascular conditions while specifically improving heart failure (HF). Multiple clinical studies established how these drugs decrease HF hospitalization rates in diabetic patients while extending their effects beyond glucose control

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

benefit. Multiple types of patients with and without existing cardiovascular conditions show benefits from this medication which thus makes SGLT2 inhibitors functional in diverse diabetes treatment scenarios.

Introducing SGLT2 inhibitors at onset of treatment can decrease hospitalization rates and enhance patient outcomes resulting in minimized healthcare expenses. SGLT2 inhibitors provide complete heart failure prevention for diabetic patients at risk through their cardiovascular and metabolic treatment benefits. Research findings demonstrate that SGLT2 inhibitors should be prescribed to diabetic patients with chronic kidney disease because they protect both the heart and kidneys.

Additional long-term investigation on SGLT2 inhibitor outcomes must follow the existing research evidence because it is essential to determine their economic value and effectiveness in combination heart failure treatment approaches. The development of treatment guidelines needs longitudinal research and investigation of specific patient groups including frail elderly patients and those with HFpEF to achieve optimal clinical strategies. The SGLT2 inhibitor class produces encouraging results for treating diabetes as well as cardiovascular complications from diabetes.

## REFERENCES

Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., ... & Pitt, B. (2021). Sotagliflozin in patients with diabetes and recent worsening heart failure. *New England journal of medicine*, *384*(2), 117-128. https://www.nejm.org/doi/full/10.1056/NEJMoa2030183

Cardoso, R., Graffunder, F. P., Ternes, C. M., Fernandes, A., Rocha, A. V., Fernandes, G., & Bhatt, D. L. (2021). SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. *EClinicalMedicine*, *36*. https://www.thelancet.com/pdfs/journals/eclinm/PIIS2589-5370(21)00213-3.pdf

Fawzy, A. M., Rivera-Caravaca, J. M., Underhill, P., Fauchier, L., & Lip, G. Y. (2023). Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database. *Diabetes, Obesity and Metabolism*, *25*(2), 602-610. https://dom-pubs.onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.14854

Keller, D. M., Ahmed, N., Tariq, H., Walgamage, M., Walgamage, T., Mohammed, A., ... & Straburzyńska-Migaj, E. (2022). SGLT2 inhibitors in type 2 diabetes mellitus and heart failure—a concise review. *Journal of Clinical Medicine*, *11*(6), 1470. https://www.mdpi.com/2077-0383/11/6/1470

Kim, H. M., Hwang, I. C., Choi, W., Yoon, Y. E., & Cho, G. Y. (2021). Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction. *Scientific Reports*, *11*(1), 22342. https://www.nature.com/articles/s41598-021-01759-5.pdf

Li, W., Katamreddy, A., Kataria, R., Myerson, M. L., & Taub, C. C. (2021). Sodium-Glucose cotransporter-2 inhibitor use is associated with a reduced risk of heart failure hospitalization in patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus: a real-world study on a diverse urban population. *Drugs-Real World Outcomes*, 1-10. https://link.springer.com/content/pdf/10.1007/s40801-021-00277-0.pdf

Nakai, M., Iwanaga, Y., Kanaoka, K., Sumita, Y., Nishioka, Y., Myojin, T., ... & Miyamoto, Y. (2022). Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society. *Cardiovascular Diabetology*, *21*(1), 157. https://link.springer.com/content/pdf/10.1186/s12933-022-01586-6.pdf

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Salah, H. M., Al'Aref, S. J., Khan, M. S., Al-Hawwas, M., Vallurupalli, S., Mehta, J. L., ... & Fudim, M. (2022). Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. *Cardiovascular Diabetology*, *21*(1), 20. https://link.springer.com/content/pdf/10.1186/s12933-022-01455-2.pdf

Singh, A. K., & Singh, R. (2021). Cardiovascular outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, *15*(1), 351-359. https://www.researchgate.net/profile/Awadhesh-Singh-4/publication/348621363_Cardiovascular_Outcomes_with_SGLT-2_inhibitors_in_patients_with_heart_failure_with_or_without_type_2_diabetes_A_systematic_review_and_meta-analysis_of_randomized_controlled_trials/links/60080251a6fdccdcb868be23/Cardiovascular-Outcomes-with-SGLT-2-inhibitors-in-patients-with-heart-failure-with-or-without-type-2-diabetes-A-systematic-review-and-meta-analysis-of-randomized-controlled-trials.pdf

Szarek, M., Bhatt, D. L., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., ... & SOLOIST-WHF committees and investigators. (2021). Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: a randomized trial. *Annals of internal medicine*, *174*(8), 1065-1072. https://researchportal.helsinki.fi/files/174225705/m21_0651.pdf

Talha, K. M., Anker, S. D., & Butler, J. (2023). SGLT-2 inhibitors in heart failure: a review of current evidence. *International Journal of Heart Failure*, *5*(2), 82. https://pmc.ncbi.nlm.nih.gov/articles/PMC10172076/pdf/ijhf-5-82.pdf

Tsampasian, V., Baral, R., Chattopadhyay, R., Debski, M., Joshi, S. S., Reinhold, J., ... & Vassiliou, V. S. (2021). The role of SGLT2 inhibitors in heart failure: a systematic review and meta-analysis. *Cardiology research and practice*, *2021*(1),9927533.https://onlinelibrary.wiley.com/doi/pdf/10.1155/2021/9927533

Ul Amin, N., Sabir, F., Amin, T., Sarfraz, Z., Sarfraz, A., Robles-Velasco, K., & Cherrez-Ojeda, I. (2022, November). SGLT2 inhibitors in acute heart failure: a meta-analysis of randomized controlled trials. In *Healthcare* (Vol. 10, No. 12, p. 2356). MDPI. https://www.mdpi.com/2227-9032/10/12/2356

Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., ... & Solomon, S. D. (2022). SGLT2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials. *The Lancet*, *400*(10354), 757-767. https://research.rug.nl/files/240676035/1_s2.0_S0140673622014295_main.pdf

Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., ... & Ponikowski, P. (2022). The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. *Nature medicine*, *28*(3), 568-574. https://www.nature.com/articles/s41591-021-01659-1.pdf

Wright, A. K., Carr, M. J., Kontopantelis, E., Leelarathna, L., Thabit, H., Emsley, R., ... & Rutter, M. K. (2022). Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. *Diabetes Care*, *45*(4), 909-918. https://eprints.gla.ac.uk/263454/2/263454Suppl.pdf

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Xie, Y., Wei, Y., Li, D., Pu, J., Ding, H., & Zhang, X. (2023). Mechanisms of SGLT2 inhibitors in heart failure and their clinical value. *Journal of Cardiovascular Pharmacology*, *81*(1), 4-14. https://www.researchgate.net/profile/Yafei-Xie 2/publication/366927608_Mechanisms_of_SGLT2_Inhibitors_in_Heart_Failure_and_Their_Clinical_Value/links/646adf87c9802f2f72eeb48d/Mechanisms-of-SGLT2-Inhibitors-in-Heart-Failure-and-Their-Clinical-Value.pdf

**Appendix: Tables**

**Table 1: Summary of Key Randomized Controlled Trials (RCTs) on SGLT2 Inhibitors and HF Hospitalizations**

| Study Name | Drug Used | Population | Primary Outcome | Results |
|---|---|---|---|---|
| DAPA-HF | Dapagliflozin | HFrEF (T2DM and non-T2DM) | Composite of worsening HF or CV death | 26% risk reduction in worsening HF or CV death (Wright et al., 2022) |
| EMPEROR-Reduced | Empagliflozin | HFrEF | HF hospitalizations and CV death | 25% risk reduction in HF hospitalization (Bhatt et al., 2021) |
| SOLOIST-WHF | Sotagliflozin | Recently hospitalized with diabetes | First and total HF hospitalizations | Significant reduction in HF hospitalizations (Szarek et al., 2021) |
| EMPULSE | Empagliflozin | Acute HF hospitalization | Clinical outcomes post-hospitalization | Improved outcomes within 90 days post-hospitalization (Voors et al., 2022) |

**Table 2: Meta-Analysis Results on SGLT2 Inhibitors and HF Hospitalizations**

| Meta-Analysis Study | Number of RCTs Included | Population Type | Outcome Measured | Results |
|---|---|---|---|---|
| Cardoso et al. (2021) | 11 | T2DM patients | HF hospitalizations | 33% reduction in HF hospitalization (Cardoso et al., 2021) |
| Salah et al. (2022) | 12 | T2DM (with and without prior cardiovascular disease) | HF hospitalization and CV outcomes | Consistent reduction in HF hospitalization across subgroups (Salah et al., 2022) |
| Ul Amin et al. (2022) | 9 | T2DM patients | Acute HF hospitalization | Significant reduction in acute HF hospitalizations with early initiation (Ul Amin et al., 2022) |

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

**Table 3: Comparative Effectiveness of SGLT2 Inhibitors vs Other Antidiabetic Agents in HF Hospitalizations**

| Drug Class | Effect on HF Hospitalization | Notes |
|---|---|---|
| SGLT2 Inhibitors | Significant reduction | Proven to reduce HF hospitalizations in T2DM patients, both with and without established HF. |
| DPP-4 Inhibitors | Neutral | No significant reduction in HF hospitalization (Nakai et al., 2022). |
| GLP-1 Receptor Agonists | Moderate effect | Some reduction in cardiovascular events but less impact on HF hospitalization compared to SGLT2 inhibitors (Nakai et al., 2022). |

**Table 4: Safety Profile of SGLT2 Inhibitors**

| Adverse Effect | Frequency | Management Strategies |
|---|---|---|
| Genital infections | Common (2-5%) | Ensure proper hygiene and early intervention. |
| Volume depletion | Rare (<1%) | Monitor renal function and blood pressure. |
| Diabetic ketoacidosis | Rare (<1%) | Discontinue use in patients with ketoacidosis. |
| UTI | Common (2-5%) | Early treatment with antibiotics if necessary. |
| Hypotension | Rare (<1%) | Monitor for signs of hypotension, particularly in elderly patients. |

**Table 5: Real-World Evidence on SGLT2 Inhibitors and HF Hospitalizations**

| Study | Population | Outcome Measured | Results |
|---|---|---|---|
| Li et al. (2021) | Urban T2DM patients | HF hospitalizations | 30% reduction in HF hospitalization in SGLT2 inhibitor users. |
| Fawzy et al. (2023) | Federated EMR data from diverse clinics | Incident HF | Lower risk of incident HF in SGLT2 users compared to other oral hypoglycemics. |